ASH 2014 | ASH 2014: Novel treatments for mantle cell lymphoma

Jia Ruan

Dr Jia Ruan (Weill Cornell Medical College, New York, NY) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses novel combination therapies that are currently being investigated in the clinic to address the unmet need in mantle cell lymphoma treatment. These therapeutic agents include bortezomib, lenalidomide, ibrutinib and rituximab.

Share this video  
Similar topics
Related videos
1:39
Venetoclax monotherapy in MCL: longer-term results
Matthew Davids
2:40
Successful use of zanubrutinib for R/R MCL in China
Yuqin Song
2:41
RB/RC induction for mantle cell lymphoma: promising pooled analysis data
Reid Merryman
4:01
VR-CAP beats R-CHOP for frontline MCL
Tadeusz Robak
Reversible BTK inhibitor ARQ 531 for CLL and NHL
Jennifer Woyach
Mantle Cell Lymphoma
Bortezomib, Ibrutinib, Lenalidomide
ASH 2014
5th December 2014
More from Jia Ruan
Novel agent therapies are improving R/R PTCL outcomes
ASH 2014: Phase II study of lenalidomide plus rituximab for mantle cell lymphoma (Part 1)
Improved outcomes in PTCL with the use of novel agents and transplantation
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals